The serine protease inhibitor Rv3364c
of Mycobacterium
tuberculosis (MTB) is highly expressed in cells during
MTB exposure. In this study, we showed that the 12WLVSKF17 motif of Rv3364c interacts with the BAR domain of SNX9 and
inhibits endosome trafficking to interact with p47phox, thereby suppressing
TLR4 inflammatory signaling in macrophages. Derived from the structure
of this Rv3364c peptide motif, 2,4-diamino-6-(4-tert-butylphenyl)-1,3,5-trazine, DATPT as a 12WLVSKF17 peptide-mimetic small molecule has been identified. DATPT can block the SNX9–p47phox interaction in the
endosome and suppress reactive oxygen species and inflammatory cytokine
production; it demonstrated significant therapeutic effects in a mouse
model of cecal ligation and puncture-induced sepsis. DATPT has considerably improved potency, with an IC50 500-fold
(in vitro) or 2000-fold (in vivo) lower than that of the 12WLVSKF17 peptide.
Furthermore, DATPT shows potent antibacterial activities
by reduction in ATP production and leakage of intracellular ATP out
of bacteria. These results provide evidence for peptide-derived small
molecule DATPT with anti-inflammatory and antibacterial
functions for the treatment of sepsis.